Physician profile
Thomas William Brown
NPI 1609976612
$19,148.54
in general payments reported to CMS, 2019-2025
67 companies · $3,014 in 2025
The $3,014 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,142 · 2020: $2,193 · 2021: $3,399 · 2022: $3,183 · 2023: $2,712 · 2024: $2,504 · 2025: $3,014.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,633 · Education: $598.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,632.83 |
| Education | $597.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $2,745.74 | 2019-2025 | Opdivo, Opdualag, Augtyro |
| Novartis Pharmaceuticals Corporation | $1,463.40 | 2019-2025 | |
| Amgen INC. | $1,387.20 | 2019-2025 | Evenity, Prolia, Lumakras |
| Astrazeneca Pharmaceuticals LP | $1,227.85 | 2019-2025 | Calquence, Lynparza, Imfinzi |
| Merck Sharp & Dohme LLC | $1,219.04 | 2019-2025 | Keytruda, Lynparza |
| Janssen Biotech, INC. | $1,181.20 | 2019-2025 | Darzalex, Erleada, Talvey |
| Pfizer INC. | $999.97 | 2019-2025 | |
| Astellas Pharma US INC | $912.08 | 2020-2025 | Xtandi, Padcev, Vyloy |
| Celgene Corporation | $732.96 | 2019-2025 | Reblozyl, Pomalyst, Opdualag |
| Regeneron Healthcare Solutions, INC. | $635.71 | 2021-2025 | Libtayo |
| Incyte Corporation | $509.21 | 2021-2025 | Jakafi, Monjuvi, Pemazyre |
| Eisai INC. | $499.95 | 2019-2025 | |
| Lilly USA, LLC | $494.05 | 2019-2025 | Verzenio, Jaypirca, Retevmo |
| Genentech USA, INC. | $485.93 | 2019-2025 | Polivy, Tecentriq, Venclexta |
| Bayer Healthcare Pharmaceuticals INC. | $426.50 | 2019-2025 |
Show all 67 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.